
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Medical care of a dying child is usually managed by a team of specialists. The primary care pediatrician&s role is supportive, with emphasis on helping the entire family cope.






